查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2003548

全球气喘治疗市场：按给药途径、药物、应用、组织类型和地区划分－市场规模、产业动态、机会分析和预测（2026-2035 年）

Global Asthma Drugs Market: By Mode of Administration, By Medication, Application, Organization Type, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 260 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球气喘治疗市场正经历重大转型，从依赖大众市场吸入药物转向以高附加价值标靶生物製药为重点。这项转变反映了个人化医疗和气喘治疗领域进步的更广泛趋势，治疗方法正日益针对特定患者亚型和潜在疾病机制进行最佳化。 2025年，市场规模预计约为265.2亿美元，展现了气喘治疗产业的庞大规模。预计该市场将稳定成长，到2035年将达到约411.8亿美元。这一成长意味着2026年至2035年预测期内的复合年增长率（CAGR）为4.50%，显示市场将持续稳定成长。

推动这一预期成长的关键因素有几个。首先，包括气喘在内的慢性发炎相关呼吸道疾病在全球范围内的盛行率不断上升，持续增加对有效治疗方法的需求。人口老化和都市化进程加快，导致人们更频繁地接触污染和过敏原等环境因素，加剧了患者数量的增长。其次，生物製药的引入正在迅速推进。这些先进治疗方法针对气喘中涉及的特定发炎通路，能够改善中重度气喘患者的治疗效果，尤其对于无法透过传统吸入药物有效控制症状的患者。

显着的市场趋势

气喘治疗市场竞争异常激烈，主要受大型製药企业策略性产品系列和标靶生物製药不断涌现的影响。Astra ZenecaGlaxoSmithKline Plc（GSK）和赛诺菲（与再生元合作）等主要企业，以及梯瓦和贝翠丝等强大的学名药生产商，共同主导着市场。这些公司凭藉其强大的研发能力，不断创新并拓展产品线，力求在满足气喘患者不断变化的需求的同时，维持并提升市场占有率。

这些製药巨头的重点之一是开发和商业化结合支气管扩张剂和皮质类固醇的联合治疗。这种方法简化了患者的治疗方法，减少了所需的吸入器和药物数量，从而提高了患者的用药依从性，并改善了疾病的整体控制。透过提供固定剂量组合药物，这些公司提供了一种更方便有效的选择，可以同时解决支气管收缩和气道发炎问题，这对于控制气喘症状和预防气喘急性发作至关重要。

除了这些联合治疗外，目前也非常重视开发针对气喘相关特定发炎路径的新型生物製药。这些生物製药代表着一个快速成长的市场领域，为对传统治疗方法反应不佳的中重度气喘患者提供了个人化的治疗选择。葛兰素史克（GSK）的长效生物製药製剂Exdensur于2025年12月获得FDA核准，这是一个值得关注的创新案例。 Exdensur旨在持续控制气喘症状，这也标誌着葛兰素史克在监管领域取得了一年的成功。

主要成长驱动因素

在亚太地区，气喘盛行率激增，主要原因是污染加剧和环境因素，这显着推动了市场成长。与气喘盛行率相对稳定的西方国家不同，亚太地区因污染引发的气喘急性发作病例显着增加，其中包括一种称为「雷暴气喘」的现象。这种疾病是指特定天气模式与高浓度花粉和污染结合，引发突发性严重气喘发作，常常对医疗系统造成巨大压力。此类事件发生频率的增加凸显了该地区居民面临的日益严峻的呼吸系统挑战。

新增长机会的趋势

儿童生物製药的拓展正成为气喘治疗市场的重要成长机会。传统上，生物製药（针对气喘特定路径的先进药物）主要核准用于成人患者和年龄较大的青少年。然而，美国食品药物管理局（FDA）和欧洲药品管理局（EMA）等监管机构正逐步降低这些治疗方法的核准年龄。例如，领先的生物製药Dupixent（度普利尤单抗）最近核准用于6岁及以上儿童。

优化障碍

由于两种重磅复方製剂－信必可（Symbicort）和舒利迭（Advair）的仿製药一般化，气喘药物市场正面临潜在的成长挑战。这些药物结合了皮质类固醇和长效β2受体激动剂，多年来一直是气喘治疗的基石，为製药公司带来了丰厚的利润。然而，已通过核准的活性成分布地Budesonide/Budesonide的学名药药获批上市后，市场供应日益饱和，价格竞争也愈演愈烈。学名药的涌入不可避免地对品牌药的销售造成压力，侵蚀市场份额，并降低整体盈利。

目录

第一章执行摘要：全球气喘治疗市场

第二章：调查方法与研究框架

  • 研究目标
  • 产品概述
  • 市场区隔
  • 定性研究
    • 一手和二手资讯
  • 量化研究
    • 一手和二手资讯
  • 初步调查受访者组成：依地区划分
  • 本研究的先决条件
  • 市场规模估算
  • 数据检验

第三章：全球气喘治疗市场概览

  • 产业价值链分析
    • 原料供应商（原料药、添加物）
    • 製药公司（原厂药厂和学名药企业）
    • 契约製造组织（CMO）
    • 经销商和批发商
    • 药房（零售和医院）
    • 医疗服务提供者（医院、诊所）
    • 最终使用者（患者）
  • 产业展望
    • 全球气喘盛行率上升
    • 空气污染加剧和环境因素增多
    • 生物製药和标靶治疗的应用日益广泛
    • 政府在呼吸系统疾病管理所做的努力
    • 药物输送系统（吸入器、雾化器）的进步
    • 医疗费用增加
    • 提高意识和早期诊断
    • 学名药市场的扩张
  • PESTLE分析
  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场动态和趋势
    • 成长驱动因素
    • 抑制因子
    • 机会
    • 主要趋势
  • 市场成长及前景
    • 市场收入估算与预测（2020-2035 年）
    • 气喘药物价格趋势分析

第四章：竞争对手仪錶板

  • 市场集中度
  • 企业市场占有率分析（以金额为准，%），2025 年
  • 竞争对手分析与基准测试
  • Start-Ups生态系分析
  • 併购和资金筹措趋势

第五章：全球气喘治疗市场分析

  • 关键见解
  • 市场规模及预测（2020-2035）
    • 透过行政途径
    • 药物
    • 透过使用
    • 按组织类型
    • 按地区

第六章：北美气喘治疗市场分析

第七章：欧洲气喘治疗市场分析

第八章：亚太地区气喘治疗市场分析

第九章：中东和非洲气喘治疗药物市场分析

第十章：南美洲气喘治疗市场分析

第十一章：公司简介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • Boehringer Ingelheim Intl. GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Ltd
  • Covis Pharma GmbH
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Lupin Ltd
  • Merck &Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Sumitomo Dainippon Pharma Co., Ltd
  • Takeda Pharmaceutical Co. Ltd
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.（Mylan）
  • 其他有潜力的企业

第十二章附录

简介目录
Product Code: AA02261710

The global asthma drugs market is undergoing a significant transformation, moving away from relying primarily on high-volume inhaler sales toward a greater emphasis on high-value targeted biologics. This shift reflects broader trends in personalized medicine and advancements in asthma treatment, where therapies are increasingly tailored to specific patient subtypes and underlying disease mechanisms. In 2025, the market was valued at approximately USD 26.52 billion, demonstrating the substantial scale of the asthma treatment landscape. Looking ahead, the market is projected to expand robustly, reaching an estimated valuation of USD 41.18 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 4.50% over the forecast period from 2026 to 2035, signaling steady and sustained market expansion.

Several key factors are driving this anticipated growth. Firstly, the rising global prevalence of chronic inflammation-related respiratory conditions, including asthma, continues to increase the demand for effective treatments. As populations age and urbanization intensifies, exposure to environmental triggers such as pollution and allergens is becoming more common, contributing to a growing patient base. Secondly, the adoption of biologics is accelerating rapidly. These advanced therapies target specific inflammatory pathways involved in asthma, offering improved outcomes for patients with moderate to severe disease who are inadequately controlled by traditional inhalers.

Noteworthy Market Developments

The asthma drugs market is highly competitive and significantly shaped by the strategic portfolios of major pharmaceutical companies, as well as the continuous introduction of new, targeted biologic therapies. Leading players such as AstraZeneca, GlaxoSmithKline (GSK), Sanofi in partnership with Regeneron, and prominent generics manufacturers like Teva and Viatris dominate the landscape. These companies leverage their extensive research and development capabilities to innovate and expand their product offerings, aiming to meet the evolving needs of asthma patients while maintaining or growing their market share.

A key focus among these pharmaceutical giants is the development and marketing of combination therapies that integrate bronchodilators with corticosteroids. This approach simplifies treatment regimens for patients by reducing the number of inhalers or medications required, improving adherence, and overall disease management. By offering fixed-dose combinations, companies provide more convenient and effective options that address both bronchoconstriction and airway inflammation simultaneously, which is crucial for controlling asthma symptoms and preventing exacerbations.

Alongside these combination therapies, there is a strong emphasis on the creation of novel biologics that target specific inflammatory pathways involved in asthma. These biologic drugs represent a growing segment within the market, offering personalized treatment options for patients with moderate to severe asthma who do not respond adequately to conventional therapies. A notable example of this innovation occurred in December 2025, when GSK capped off a year of regulatory successes by securing FDA approval for Exdensur, a long-acting biologic designed to provide sustained control of asthma symptoms.

Core Growth Drivers

The Asia-Pacific (APAC) region is experiencing a notable surge in asthma prevalence, driven largely by escalating pollution levels and environmental factors, which are significantly fueling market growth. Unlike Western countries, where asthma prevalence has largely stabilized, APAC is witnessing an alarming increase in cases related to pollution-triggered exacerbations, including a phenomenon known as "Thunderstorm Asthma." This condition occurs when specific weather patterns, combined with high pollen and pollution levels, trigger sudden and severe asthma attacks, often overwhelming healthcare systems. The rising frequency of such events underscores the growing respiratory health challenges faced by populations in this region.

Emerging Opportunity Trends

Pediatric biologic expansion is emerging as a significant growth opportunity within the asthma drugs market. Traditionally, biologic therapies-advanced medications designed to target specific pathways involved in asthma-have been predominantly approved for adult patients or older adolescents. However, regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are progressively lowering the approved age thresholds for these treatments. For example, Dupixent (dupilumab), a leading biologic, has recently been approved for use in children aged six and older.

Barriers to Optimization

The asthma drugs market faces potential challenges to its growth due to the generic erosion of two blockbuster combination therapies: Symbicort and Advair. These medications, which combine corticosteroids and long-acting beta-agonists, have long been mainstays in asthma management and have generated substantial revenue for pharmaceutical companies. However, the increasing availability of authorized generics for Budesonide/Formoterol, the active ingredients in Symbicort, is saturating the market and intensifying price competition. This influx of generics inevitably puts pressure on the sales of branded products, eroding their market share and reducing overall profitability.

Detailed Market Segmentation

Based on Mode of Administration, the inhalers segment commanded the highest revenue share in the asthma drugs market, establishing the inhaled route as the preferred mode of administration. This dominance extends beyond the clinical advantages of inhaled therapies, which have long been recognized for delivering medication directly to the lungs with rapid onset and targeted effect. Instead, the leading position of inhalers is now structurally reinforced by what industry experts refer to as the "Device Fortress."

Based on Medication, the quick relief medications segment, primarily composed of short-acting beta-agonists (SABAs), held the largest share of the asthma drugs market. This dominance is not due to these medications being considered the clinical gold standard for asthma management, but rather because they are uniquely "climate-elastic" within the broader respiratory drug portfolio.

Based on Organization Type, the public segment is expected to hold the largest share of the asthma drugs market, underscoring the significant role played by government and publicly funded healthcare organizations in managing asthma treatment. This dominance is closely linked to the phenomenon known as "adverse selection" within insurance markets, where individuals with more severe and uncontrolled asthma disproportionately belong to lower-income groups and elderly populations.

Based on Application, the adult segment emerged as the largest market share holder within the asthma drugs market, reflecting its dominant role in this therapeutic area. This prominence is largely due to the adult population being the primary demographic capable of benefiting from and monetizing advancements in precision medicine. Precision medicine, which tailors treatment based on individual patient characteristics and biomarkers, has gained significant traction in adult asthma management, leading to more effective and targeted therapies.

Segment Breakdown

By Medication

  • Quick Relief Medications
  • Long-term Control Medications
  • Others

By Mode of Administration

  • Tablets and Capsules
  • Liquids
  • Inhalers
  • Injections

By Organization Type

  • Public
  • Private

By Application

  • Pediatric
  • Adults
  • Adolescent

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America is poised to maintain its leadership position in the global asthma drugs market, commanding a substantial 47% share. This dominant market presence is largely driven by the United States, where a significant portion of asthma treatments are developed and consumed. However, the US asthma drugs market faces unique challenges, including the impact of the Pharmacy Benefit Manager (PBM) rebate system, often referred to as the "PBM Rebate Wall." This system affects drug pricing and accessibility, creating complexities that influence market dynamics and patient access to therapies.
  • Compounding this environment is the introduction of the Inflation Reduction Act (IRA), set to take effect in 2026, which aims to negotiate drug prices to reduce costs for consumers. The initial list of ten drugs selected for price negotiation under the IRA predominantly targets cardiovascular and diabetes medications, such as Eliquis and Jardiance, reflecting the government's focus on high-spending drug categories.

Leading Market Participants

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • Boehringer Ingelheim Intl. GmbH
  • Chiesi Farmaceutici S.p.A.
  • Cipla Ltd
  • Covis Pharma GmbH
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Lupin Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Sumitomo Dainippon Pharma Co., Ltd
  • Takeda Pharmaceutical Co. Ltd
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc. (Mylan)
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Asthma Drugs Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Asthma Drugs Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers (APIs, Excipients)
    • 3.1.2. Drug Manufacturers (Innovator & Generic Companies)
    • 3.1.3. Contract Manufacturing Organizations (CMOs)
    • 3.1.4. Distributors & Wholesalers
    • 3.1.5. Pharmacies (Retail & Hospital)
    • 3.1.6. Healthcare Providers (Hospitals, Clinics)
    • 3.1.7. End Users (Patients)
  • 3.2. Industry Outlook
    • 3.2.1. Rising Prevalence of Asthma Globally
    • 3.2.2. Increasing Air Pollution & Environmental Triggers
    • 3.2.3. Growing Adoption of Biologics & Targeted Therapies
    • 3.2.4. Government Initiatives for Respiratory Disease Management
    • 3.2.5. Advancements in Drug Delivery Systems (Inhalers, Nebulizers)
    • 3.2.6. Increasing Healthcare Expenditure
    • 3.2.7. Rising Awareness & Early Diagnosis
    • 3.2.8. Expansion of Generic Drug Market
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Dynamics and Trends
    • 3.5.1. Growth Drivers
      • 3.5.1.1. Rising Prevalence of Asthma and Respiratory Disorders
    • 3.5.2. Restraints
    • 3.5.3. Opportunity
    • 3.5.4. Key Trend
  • 3.6. Market Growth and Outlook
    • 3.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2035
    • 3.6.2. Price Trend Analysis, of Asthma Drugs

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking
  • 4.4. Startup Ecosystem Analysis
  • 4.5. M&A and Funding Landscape

Chapter 5. Global Asthma Drugs Market Analysis

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Mode Of Administration
      • 5.2.1.1. Injections
      • 5.2.1.2. Liquids
      • 5.2.1.3. Tablets And Capsules
      • 5.2.1.4. Inhalers
    • 5.2.2. By Medication
      • 5.2.2.1. Long-Term Control Medications
      • 5.2.2.2. Quick Relief Medications
      • 5.2.2.3. Others
    • 5.2.3. By Application
      • 5.2.3.1. Adults
      • 5.2.3.2. Pediatric
      • 5.2.3.3. Adolescent
    • 5.2.4. By Organization Type
      • 5.2.4.1. Private
      • 5.2.4.2. Public
    • 5.2.5. By Region
      • 5.2.5.1. North America
        • 5.2.5.1.1. The U.S.
        • 5.2.5.1.2. Canada
        • 5.2.5.1.3. Mexico
      • 5.2.5.2. Europe
        • 5.2.5.2.1. Western Europe
          • 5.2.5.2.1.1. The UK
          • 5.2.5.2.1.2. Germany
          • 5.2.5.2.1.3. France
          • 5.2.5.2.1.4. Italy
          • 5.2.5.2.1.5. Spain
          • 5.2.5.2.1.6. Rest of Western Europe
        • 5.2.5.2.2. Eastern Europe
          • 5.2.5.2.2.1. Poland
          • 5.2.5.2.2.2. Russia
          • 5.2.5.2.2.3. Rest of Eastern Europe
      • 5.2.5.3. Asia Pacific
        • 5.2.5.3.1. China
        • 5.2.5.3.2. India
        • 5.2.5.3.3. Japan
        • 5.2.5.3.4. South Korea
        • 5.2.5.3.5. Australia & New Zealand
        • 5.2.5.3.6. ASEAN
          • 5.2.5.3.6.1. Indonesia
          • 5.2.5.3.6.2. Malaysia
          • 5.2.5.3.6.3. Thailand
          • 5.2.5.3.6.4. Singapore
          • 5.2.5.3.6.5. Rest of ASEAN
        • 5.2.5.3.7. Rest of Asia Pacific
      • 5.2.5.4. Middle East & Africa
        • 5.2.5.4.1. UAE
        • 5.2.5.4.2. Saudi Arabia
        • 5.2.5.4.3. South Africa
        • 5.2.5.4.4. Rest of MEA
      • 5.2.5.5. South America
        • 5.2.5.5.1. Argentina
        • 5.2.5.5.2. Brazil
        • 5.2.5.5.3. Rest of South America

Chapter 6. North America Asthma Drugs Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Mode Of Administration
    • 6.2.2. By Medication
    • 6.2.3. Application
    • 6.2.4. Organization Type
    • 6.2.5. By Country

Chapter 7. Europe Asthma Drugs Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Mode Of Administration
    • 7.2.2. By Medication
    • 7.2.3. Application
    • 7.2.4. Organization Type
    • 7.2.5. By Country

Chapter 8. Asia Pacific Asthma Drugs Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Mode Of Administration
    • 8.2.2. By Medication
    • 8.2.3. Application
    • 8.2.4. Organization Type
    • 8.2.5. By Country

Chapter 9. Middle East & Africa Asthma Drugs Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Mode Of Administration
    • 9.2.2. By Medication
    • 9.2.3. Application
    • 9.2.4. Organization Type
    • 9.2.5. By Country

Chapter 10. South America Asthma Drugs Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Mode Of Administration
    • 10.2.2. By Medication
    • 10.2.3. Application
    • 10.2.4. Organization Type
    • 10.2.5. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. AbbVie Inc.
  • 11.2. Amgen Inc.
  • 11.3. AstraZeneca
  • 11.4. Boehringer Ingelheim Intl. GmbH
  • 11.5. Chiesi Farmaceutici S.p.A.
  • 11.6. Cipla Ltd
  • 11.7. Covis Pharma GmbH
  • 11.8. F. Hoffmann-La Roche Ltd
  • 11.9. GlaxoSmithKline plc
  • 11.10. Lupin Ltd
  • 11.11. Merck & Co., Inc.
  • 11.12. Novartis AG
  • 11.13. Orion Corporation
  • 11.14. Pfizer Inc.
  • 11.15. Regeneron Pharmaceuticals Inc.
  • 11.16. Sanofi
  • 11.17. Sumitomo Dainippon Pharma Co., Ltd
  • 11.18. Takeda Pharmaceutical Co. Ltd
  • 11.19. Teva Pharmaceutical Industries Ltd
  • 11.20. Viatris Inc. (Mylan)
  • 11.21. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Macro-Economic Outlook/Indicators